Intellia Therapeutics, Inc. (NTLA)
Automate Your Wheel Strategy on NTLA
With Tiblio's Option Bot, you can configure your own wheel strategy including NTLA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NTLA
- Rev/Share 0.5096
- Book/Share 6.8952
- PB 2.9644
- Debt/Equity 0.1434
- CurrentRatio 5.1932
- ROIC -0.6166
- MktCap 2194170350.0
- FreeCF/Share -4.0664
- PFCF -5.2017
- PE -4.4155
- Debt/Assets 0.1141
- DivYield 0
- ROE -0.5769
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NTLA | Wolfe Research | Peer Perform | Outperform | -- | $21 | April 21, 2025 |
| Initiation | NTLA | H.C. Wainwright | -- | Buy | -- | $30 | March 5, 2025 |
| Downgrade | NTLA | Goldman | Neutral | Sell | -- | $9 | Feb. 28, 2025 |
| Downgrade | NTLA | JP Morgan | Overweight | Neutral | $45 | $13 | Feb. 28, 2025 |
| Downgrade | NTLA | Morgan Stanley | Overweight | Equal Weight | $56 | $11 | Jan. 27, 2025 |
News
April 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NTLA
Published: March 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.
Read More
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Published: March 21, 2025 by: The Motley Fool
Sentiment: Positive
The last few weeks of cascading share prices may be troublesome to most investors, but Cathie Wood doesn't mind buying during the deluge. The co-founder, CEO, and investment manager at Ark Invest has been more active lately in buying shares for her high-octane growth exchange-traded funds.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Published: March 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Published: March 21, 2025 by: Accesswire
Sentiment: Neutral
EW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=137759&wire=1 or contact Joseph E. Levi, Esq.
Read More
NTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 21, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , March 21, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ: NTLA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 30, 2024 and January 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2025.
Read More
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).
Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Published: March 20, 2025 by: Accesswire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Intellia To Contact Him Directly To Discuss Their Options NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you purchased or acquired securities in Intellia between July 30, 2024 and January 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Intellia Therapeutics, Inc. …
Read More
NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: March 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Intellia securities between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period").
Read More
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc.(NTLA) Shareholders
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Intellia Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=137304&wire=1 or contact Joseph E. Levi, Esq.
Read More
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit
Published: March 19, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 19, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. So what: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Investors Who Lost Money on Intellia Therapeutics, Inc. (NTLA) Should Contact Levi & Korsinsky about Pending Class Action - NTLA
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=137192&wire=1 or contact Joseph E. Levi, Esq.
Read More
Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=137164&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Published: March 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 18, 2025 / WHY: New York, N.Y., March 18, 2025.
Read More
Levi & Korsinsky Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Published: March 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 17, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=136672&wire=1 or contact Joseph E. Levi, Esq.
Read More
Investors who lost money on Intellia Therapeutics, Inc.(NTLA) should contact The Gross Law Firm about pending Class Action - NTLA
Published: March 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Published: March 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ :NTLA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Published: March 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ:NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2024 lead plaintiff deadline. SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc. (NTLA) Shareholders
Published: March 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.
Read More
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=135778&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Published: March 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ: NTLA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class Action Lawsuit and an Upcoming Deadline
Published: March 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=135244&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Published: March 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their Options
Read More
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: March 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=135033&wire=1 or contact Joseph E. Levi, Esq.
Read More
Contact Levi & Korsinsky by April 14, 2025 Deadline to Join Class Action Against Intellia Therapeutics, Inc. (NTLA)
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.
Read More
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit
Published: March 10, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 10, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – NTLA
Published: March 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
About Intellia Therapeutics, Inc. (NTLA)
- IPO Date 2016-05-06
- Website https://www.intelliatx.com
- Industry Biotechnology
- CEO John M. Leonard
- Employees 403